InSysBio LLC Announce Renewal of Agreement with ASTEX Pharmaceuticals Inc.

NEWS
Press-Release
July 25, 2017

Moscow, Russia, July 25, 2017InSysBio LLC (www.insysbio.ru), one of the pioneers in Quantitative Systems Pharmacology (QSP) modeling and simulation for drug development, announced today a renewal of multi-year Master Service Agreement with ASTEX Pharmaceuticals, Inc.

Within the framework of this cooperation, InSysBio provides priority support for ASTEX research. This gives an opportunity to access the best practices of InSysBio in the field of QSP modeling, as well as significantly reduce the time of initiation and execution of projects.

The renewal of the ASTEX agreement once again shows that QSP is a necessary technology to support discovery and development of new drugs in oncology and immuno-oncology therapeutic areas. Such an approach improves all stages of the development: it helps to make strategic GO/ NO GO decisions for research, prioritize targets and compounds, interpret results from animal studies and select optimal design(s) for clinical trials.

"We are very pleased ASTEX has chosen to renew our multi-year Master Service Agreement. It underscores that our partners are satisfied with our services and would like to extend this fruitful and reliable collaboration," said Founder and CEO Oleg Demin, PhD.

September 2024
MoTuWeThFrSaSu
      
1
2
3
4
1. 04 Sep 2024 16:07 Now B cells model reflects the current views on the processes InSysBio launches Immune Response Template (IRT) version 3.6.3. IRT represents a QSP platform of immune system, simultaneously, being a tool for development of models related to immune system
5
6
7
8
9
10
1. 10 Sep 2024 18:36 InSysBio team to publish the new article in PSPJournal The new article "Quantitative systems pharmacology model of α-synuclein pathology in Parkinson's disease-like mouse for investigation of passive immunotherapy mechanisms" by Olga Ivanova and Tatiana Karelina was published in PSPJournal at the end of August 2024
11
1. 11 Sep 2024 15:25 InSysBio to take part in ACoP 2024 InSysBio announces its participation in the 15th American Conference on Pharmacometrics (ACoP). Oleg Demin Jr, Scientific Director, Oncology & Immuno-Oncology, will be a co-chair and speaker of the session "Advancing QSP: From Virtual Patient To Digital Twin". InSysBio team is going to present its modeling services & software to optimize drug development at the Booth #11 and 9 posters in frames of the Conference
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
      
Upcoming Events
10.11
InSysBio to take part in ACoP 2024
Tags
Latest News
10.09
InSysBio team to publish the new article in PSPJournal
04.09
InSysBio to launch Immune Response Template version 3.6.3 for QSP modeling
22.02
14th InSysBio’s Annual Internal Scientific Meeting
24.01
InSysBio to present the new Plugin for Sublime Text and Heta compiler Online
07.12
InSysBio to release public beta of fIVE Calculator